Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study

Abstract

<p id="d10907359e285"> <div class="list"> <a class="named-anchor" id="d10907359e287"> <!-- named anchor --> </a> <ul class="so-custom-list"> <li id="d10907359e288"> <div class="so-custom-list-content so-ol"> <p class="first" id="d10907359e289">Patients who received R-chemo followed by MR had an improved 5-year PFS and OS independent of prognostic factors. </p> </div> </li> <li id="d10907359e291"> <div class="so-custom-list-content so-ol"> <p class="first" id="d10907359e292">A reduction of the risk of HT was observed among the MR patients of the training, but not of the validation, cohort. </p> </div> </li> </ul> </div> </p><p class="first" id="d10907359e296">The introduction of the anti-CD20 antibody rituximab in combination with chemotherapy (R-chemo) has improved the prognosis of patients with follicular lymphoma (FL). During the last decade, the addition of a maintenance treatment with rituximab (MR) after R-chemo has been tested with the hope of further improving the outcome of these patients. Using 2 independent population-based cohorts, we investigated the effect of up-front MR on time related end points as well as the risk of histological transformation (HT). FL patients were included if they: (1) completed first-line induction treatment with R-chemo, (2) were alive after induction treatment and eligible for MR, and (3) had no evidence of HT at this time point. The training cohort consisted of 733 Danish patients of whom 364 were consolidated with MR; 369 were not. Patients receiving MR more often had advanced clinical stage (90% vs 78%), high Follicular Lymphoma International Prognostic Index (FLIPI) score (64% vs 55%), and bone marrow infiltration (49% vs 40%). Those consolidated with MR had an improved 5-year overall survival (OS; 89% vs 81%; <i>P</i> = .001) and progression-free survival (PFS; 72% vs 60%; <i>P</i> &lt; .001). In the training cohort, MR was associated with a reduction of HT risk ( <i>P</i> = .049). Analyses of an independent validation cohort of 190 Finnish patients confirmed the favorable impact of MR on 5-year OS (89% vs 81%; <i>P</i> = .046) and PFS (70% vs 57%; <i>P</i> = .005) but did not find a reduced risk of HT. The present population-based data suggest that the outcome of patients with FL has improved after consolidation of R-chemo with MR. </p><p id="d10907359e317"> <div class="fig panel" id="absf1"> <a class="named-anchor" id="absf1"> <!-- named anchor --> </a> <div class="figure-container so-text-align-c"> <img alt="" class="figure" src="/document_file/064aa3e6-39ce-49ae-a318-84eb8c7795bc/PubMedCentral/image/advances017673absf1"/> </div> <div class="panel-content"/> </div> </p>